Document text
Principal Investigator: Scott M Husson
Organization: CLEMSON UNIVERSITY
Fiscal Year: 2022
Award: $217,771
Funding agency: National Institute of General Medical Sciences
Project Summary
Circular RNA (circRNA) has important, understudied roles all across physiology and disease. Additionally,
circularization of protein-coding RNA is a promising strategy for increasing the duration and quantity of
therapeutic protein production and decreasing immunogenicity relative to linear messenger RNA (mRNA), such
as those used to develop the first COVID-19 vaccines. Unfortunately, the synthesis of circRNA produces
solutions that contain contaminating linear RNA precursors and nicked RNA that cause cellular immune
responses; and no effective purification method has been demonstrated. The goal of this project is to test the
feasibility of a novel concept to purify circular RNA with high purity and high yield. The proposed study has
strong potential to advance biomedical research aimed at answering questions about the roles of circRNA in
disease and biological function, where high sample purity is essential. It also has the potential to have a
significant impact on the development of and access to circRNA therapies by demonstrating a high yield
approach for their purification that does not exist today. Our research hypothesis is that membrane
ultrafiltration can be used to separate RNA based on shape and size. We theorize that RNA transmission
through ultrafiltration membranes will begin to occur at a critical flux (quotient of flowrate and membrane area)
due to flow-induced elongation. Differences in elongational properties among RNA conformers will lead to
differences in critical fluxes, which provides a basis for the purification of circRNA from linear RNA impurities.
The Specific Aims are to (1) quantify ultrafiltration critical fluxes for circRNA, linear RNA precursor, and nicked
RNA; (2) develop a protocol for purification of circRNA generated from self-splicing reactions, and (3)
demonstrate protein production in cells for ultrafiltration-purified circRNA. In Aim 1, we will produce purified
fractions of the different RNA conformers and accurately measure their transmission through ultrafiltration
membranes to quantify their critical fluxes based on membrane properties. New technical knowledge
generated using purified RNA conformers will identify flux conditions that can be used for the separation of
circRNA from linear contaminants in self-splicing reaction solutions. In Aim 2, we will establish an easy to
implement protocol that exploits differences in these critical fluxes to purify circRNA from self-splicing reaction
solutions. This aim will advance knowledge on the key factors influencing circRNA purity and yield. In Aim 3,
we will measure the quantity and evaluate the stability of protein production in cells for ultrafiltration-purified
circRNA relative to circRNA purified using high-performance liquid chromatography, which represents the
state-of-the-art approach. This project will provide a clear proof of concept for ultrafiltration-based purification
of circRNA with high purity (95%) and high yield (>70%), which would be a significant advancement over the
state of the art.
Terms: <2019-nCoV vaccine><Address><Adopted><Area><Biological Function><Biological Process><Biology><Biomedical Research><COVID-19 prevention><COVID-19 vaccine><COVID19 prevention><COVID19 vaccine><Cell Body><Cell Count><Cell Number><Cells><Code><Coding System><DNA><Data><Deoxyribonucleic Acid><Development><Disease><Disorder><Emerging Communicable Diseases><Emerging Infectious Diseases><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Goals><HPLC><Half-Life><High Performance Liquid Chromatography><High Pressure Liquid Chromatography><High Speed Liquid Chromatography><Hour><Immune response><Immunological response><Knowledge><Lead><Lytotoxicity><Measures><Membrane><Messenger RNA><Methodology><Methods><Molecular Weight><Non-Polyadenylated RNA><Output><Pathology><Pb element><Performance><Physiology><Play><Polymers><Production><Property><Proteins><Protocol><Protocols documentation><RNA><RNA Conformation><RNA Gene Products><RNA Precursors><RNA Splicing><Reaction><Recovery><Research><Resolution><Ribonucleic Acid><Role><SARS-CoV-2 vaccine><SARS-CoV2 vaccine><SARS-coronavirus-2 vaccine><Sampling><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Shapes><Splicing><Structure><Technology><Therapeutic><Transmission><Ultrafiltration><Vaccine Antigen><Vaccine Production><base><circular RNA><closed circular RNA><conformer><corona virus disease 2019 vaccine><coronavirus disease 2019 prevention><coronavirus disease 2019 vaccine><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><cytotoxicity><developmental><experiment><experimental research><experimental study><feasibility testing><flow cytophotometry><heavy metal Pb><heavy metal lead><host response><immune system response><immunogenicity><immunoresponse><in vivo><innovate><innovation><innovative><live cell image><live cell imaging><live cellular image><live cellular imaging><mRNA><macromolecule><membrane structure><native protein drug><new approaches><novel><novel approaches><novel strategies><novel strategy><pharmaceutical protein><plasmid DNA><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><produce vaccines><protein drug agent><protein expression><protein-based drug><public health relevance><social role><therapeutic protein><therapeutic vaccine><transmission process><treatment vaccines><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine for the treatment><vaccine for treatment>